<DOC>
	<DOCNO>NCT00790673</DOCNO>
	<brief_summary>This trial test hypothesis CF102 safely effectively suppress viral load patient chronic hepatitis C high circulating level virus . The trial monitor safety twice-daily oral dose CF102 16-week period ; measure change viral load therapy ; measure blood concentration CF102 various time point dose .</brief_summary>
	<brief_title>A Phase 1/2 Study CF102 Patients With Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description>This Phase 1/2 , randomize , double-blind , placebo-controlled , dose-escalation study subject chronic hepatitis C genotype 1 . Eligible subject assign 3:1 ratio ( 8 subject cohort ) receive qd bid treatment 15 day oral CF-102 placebo . Dose escalation occur 2 sequential cohort . The decision continue dose within cohort ( eg , Subcohort 1a Subcohort 1b ) , escalate new dose level Cohort ( eg , Subcohort 1b Subcohort 2a ) determine blinded independent review safety data . This review conduct qualified Safety Review Committee comprise medical monitor , consult toxicologist , independent expert clinician . For first 2 cohort , subject return study center follow-up assessment Days 8 , 15 , 22 . Subjects dose qd receive total 15 dose CF-102 . Subjects dose bid receive total 29 dos . The 30th dose delete accommodate PK sample morning Day 16 , 24 hour last dose CF-102 . For 3rd cohort , subject return study center follow-up assessment week 2 , 4 , 8 , 12 , 16 18 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>1 . 18 60 year age 2 . Body mass index ≤ 30 kg/m2 3 . Either : 1. evidence cirrhosis , liver fibrosis correspond Metavir Stages 0 31 liver biopsy perform within past 2 year , 2. score F0 F1 ActiTestFibroTest perform within past year . 4 . ChildPugh score ≤ 5 Screening 5 . Serologic evidence chronic hepatitis Cinfection ( antiHCV serum ) 6 . HCV plasma RNA ≥ 1 x 105 IU/mL 2 separate sample obtain screening period . 7 . HCV genotype 1 8 . The following laboratory value must document within Screening period : Hemoglobin &gt; 11.0 g/dL female &gt; 12.0 g/dL male Platelet count &gt; 50 x109/L Normal serum creatinine Aspartic aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5fold upper limit normal International normalized ratio ( INR ) ≤ 1.3fold normal Serum albumin ≥ 3.6 gm/dL 9 . Female subject pregnant breastfeeding must either postmenopausal , surgically sterile , abstinent , use 2 proven method birth control 10 . Sexually active male subject must practice acceptable method contraception ( eg , vasectomy , use condom plus spermicide , monogamous relationship female partner practice acceptable method contraception ) treatment period 11 . Negative serum ßhuman chorionic gonadotropin ( HCG , females childbearing potential ) 12 . Provide informed consent 13 . Willing comply study requirement 1 . Positive test Screening human immunodeficiency virus 2 . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug 3 . History ongoing cardiac dysrhythmias require treatment , atrial fibrillation grade , persistent prolongation correct QT ( QTc ) ( Fridericia ) interval &gt; 450 msec male &gt; 470 msec female 4 . Positive result drug abuse Screening 5 . Donation loss 400 mL blood within 2 month prior anticipate dose administration 6 . Participation clinical study investigational drug , biologic , device within 3 month prior anticipate dose administration 7 . Previous exposure CF102 ( Cohorts 1 2 ) 8 . Males whose female partner pregnant 9 . Serum alphafetoprotein &gt; 50 ng/mL screen 10 . Any severe , acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere informed consent process and/or compliance requirement study , may interfere interpretation study result , investigator 's opinion , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Viral hepatitis</keyword>
</DOC>